Digital Genome Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The digital genome market size has grown rapidly in recent years. It will grow from $39.25 billion in 2024 to $46.94 billion in 2025 at a compound annual growth rate (CAGR) of 19.6%. The growth in the historic period can be attributed to growing funding for genomics, reduced cost and high speed of DNA sequencing, entry of new players and start-ups in developing economies, increasing number of drug discoveries, and growing biotech sector.

The digital genome market size is expected to see rapid growth in the next few years. It will grow to $97.13 billion in 2029 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing research and development pertaining to digital genome, growing adoption of personalized medicine, developments in biotechnology, and rising prevalence of chronic diseases. Major trends in the forecast period include the increasing adoption of next-generation sequencing technologies, increasing technological advancements, extensive use of microorganisms in diagnostics industry, increasing demand for personalized medicines, and rising adoption of digital genomic technology by hospitals and clinics.

The increasing prevalence of genetic disorders is expected to propel the growth of the digital genome market going forward. Genetic disorders are hereditary conditions caused by abnormalities or mutations in an individual's DNA, the genetic material that carries instructions for the development and functioning of the body. Digital genome technologies enable the identification of genetic mutations and variations associated with genetic disorders. This information helps in accurate and early diagnosis of these disorders, allowing for timely intervention and treatment. For instance, in August 2023, according to the National Library of Medicine, a US-based medical library, sickle cell anemia is a genetic disease that affects approximately 1 in 500 African Americans in the United States. Further, about 1 in 12 African Americans carries the autosomal recessive mutation responsible for the disease, and approximately 300,000 infants are born with sickle cell anemia annually. Therefore, the increasing prevalence of genetic disorders is driving the growth of the digital genome market.

Major companies operating in the digital genome market are developing innovative products such as the NovaSeq X Series to understand disease and ultimately transform patient lives. NovaSeq X Series includes the NovaSeq X and NovaSeq X Plus systems, with the NovaSeq X Plus capable of sequencing more than 128 genomes per run and generating more than 20,000 whole genomes per year. For instance, in September 2022, Illumina, Inc., a US-based biotechnology company, launched the NovaSeq X Series, a significant advancement in whole-genome sequencing technology. The system incorporates cost-efficiency throughout the workflow, streamlined informatics, operational simplicity, sustainability advancements, and world-class support. It also enables broader and deeper sequencing, allowing users to scale up any application to include more samples and analyze data more efficiently. The NovaSeq X Series is designed to be the most potent and cost-effective sequencing system, with improved reagent stability and faster data transfers due to optimized genomics data compression. The system was purpose-built for improved sustainability, with a smaller data footprint that reduces storage and energy consumption costs.

In January 2023, Agilent Technologies, a US-based company specializing in analytical solutions, acquired Avida Biomed for an undisclosed amount. This acquisition is aimed at strengthening Agilent Technologies' next-generation sequencing capabilities by incorporating Avida Biomed's target enrichment workflows. Avida Biomed is a US-based life sciences company that specializes in developing advanced target enrichment workflows for next-generation sequencing (NGS).

Major companies operating in the digital genome market are Roche Holding AG, Thermo Fisher Scientific Inc., GE HealthCare Technologies Inc., Quest Diagnostics, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., bioMerieux SA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., BGI Genomics, Myriad Genetics Inc., Foundation Medicine Inc., ArcherDx Inc., Invitae Corporation, Oxford Nanopore Technologies Ltd., Luminex Corporation, GenMark Diagnostics Inc., NanoString Technologies Inc., Pacific Biosciences of California Inc., Genewiz, Inscripta Inc., Genomic Health Inc., Becton Dickinson and Company, GenomeMe, Regeneron Pharmaceuticals Inc.

North America was the largest region in the digital genome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital genome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital genome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital genome market consists of revenues earned by entities by providing services such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) isolation, profiling, qPCR, next-generation sequencing, and advanced bioinformatics data analysis pipelines. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital genome market also includes sales of sequencing and analyzer instruments, sequencing chips, sample preparation instruments, and sequencing and analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The digital genome refers to the digitized and organized collection of an organism's genetic material, including its DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) sequences. This digital representation allows for storing, analyzing, and interpreting genetic information using computational tools and technologies. Digital genomes are essential for understanding genetic variations, disease mechanisms, and evolutionary relationships.

The main types of digital genome are sequencing and analyzer instruments, and data analysis and management tools. Sequencing and analyzer instruments refer to equipment used in genomic sequencing and analysis processes, which are essential for decoding the genetic information contained within DNA and RNA molecules. They are used for various applications such as diagnostics, agriculture and animal research, personalized medicine, drug discovery, and treatment analysis by research centers and government institutes, academic institutions, pharmaceutical and biotechnology industries, hospitals, and diagnostic centers.

The main types of digital genome are sequencing and analyzer instruments, and data analysis and management tools. Sequencing and analyzer instruments refer to equipment used in genomic sequencing and analysis processes, which are essential for decoding the genetic information contained within DNA and RNA molecules. They are used for various applications such as diagnostics, agriculture and animal research, personalized medicine, drug discovery, and treatment analysis by research centers and government institutes, academic institutions, pharmaceutical and biotechnology industries, hospitals, and diagnostic centers.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.